Five cancer researchers receive 2021 New Discoveries Young Investigator Awards from BCAN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Five researchers have received the 2021 New Discoveries Young Investigator Awards from the Bladder Cancer Advocacy Network. 

This is the first year BCAN has presented five awards. 

  • The 2021 New Discoveries Young Investigator Awards went to Brendan Guercio, a Hematology/Oncology fellow at Memorial Sloan Kettering Cancer Center, and Eugene Pietzak, assistant attending surgeon (urologic oncology) at Memorial Sloan Kettering Cancer Center. Guercio’s project title is “Associations of Patient Diet and Benefit from Immunotherapy in Urothelial Carcinoma” and Pietzak’s is titled “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.”

Each Young Investigator Award provides a $50,000 grant that supports one year of early career bladder cancer research. Since 2009, BCAN has awarded more than $5.5 million to promising scientists and research investigators across the country and these awards demonstrate that the important work to improve the understanding of bladder cancer and its impact on patients and families continues.

  • The two 2021 Palm Beach New Discoveries Young Investigator awardees are Filipe De Carvalho, urologic oncology fellow at Brigham and Women’s Hospital, and Benjamin Miron, medical oncology fellow at Fox Chase Cancer Center.  The title of Carvalho’s awarded project is “Clonal Architecture and Tumor Microenvironment of Cisplatin Resistant Localized Muscle Invasive Bladder Cancer” and Miron’s is “Relationship of Circulating Tumor DNA in Patients with Muscle Invasive Bladder Cancer to Pathologic Staging and Disease Prognosis.”
  • The 2021 New Discoveries Young Investigator Award for Patient Centered Research was awarded to Svetlana Avulova, urologic oncology fellow at Mayo Clinic. Avulova’s project is titled “Sexual Function in Women Undergoing Radical Cystectomy.”

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login